Amgen Inc (AMGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Amgen Inc (AMGN) has a cash flow conversion efficiency ratio of 0.185x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.60 Billion) by net assets ($8.66 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Amgen Inc market capitalisation for the company's overall valuation and market capitalisation.
Amgen Inc - Cash Flow Conversion Efficiency Trend (1988–2025)
This chart illustrates how Amgen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Amgen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Amgen Inc ranked by their cash flow conversion efficiency. Explore earnings quality score of Amgen Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nestle S.A.
SW:NESN
|
0.181x |
|
HERMES INTL UNSP.ADR 1/10
F:HMIA
|
N/A |
|
Toronto Dominion Bank
TO:TD
|
-0.087x |
|
Marvell Technology Group Ltd
NASDAQ:MRVL
|
0.033x |
|
Contemporary Amperex Technology Co Ltd Class A
SHE:300750
|
0.127x |
|
Shopify Inc
NYSE:SHOP
|
0.041x |
|
Verizon Communications Inc
SA:VERZ34
|
0.099x |
|
Mitsubishi UFJ Financial Group Inc ADR
NYSE:MUFG
|
0.351x |
Annual Cash Flow Conversion Efficiency for Amgen Inc (1988–2025)
The table below shows the annual cash flow conversion efficiency of Amgen Inc from 1988 to 2025. View Amgen Inc (AMGN) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $8.66 Billion | $9.96 Billion | 1.150x | -41.17% |
| 2024-12-31 | $5.88 Billion | $11.49 Billion | 1.955x | +43.83% |
| 2023-12-31 | $6.23 Billion | $8.47 Billion | 1.359x | -48.81% |
| 2022-12-31 | $3.66 Billion | $9.72 Billion | 2.655x | +92.10% |
| 2021-12-31 | $6.70 Billion | $9.26 Billion | 1.382x | +23.90% |
| 2020-12-31 | $9.41 Billion | $10.50 Billion | 1.116x | +17.94% |
| 2019-12-31 | $9.67 Billion | $9.15 Billion | 0.946x | +4.68% |
| 2018-12-31 | $12.50 Billion | $11.30 Billion | 0.904x | +104.08% |
| 2017-12-31 | $25.24 Billion | $11.18 Billion | 0.443x | +27.77% |
| 2016-12-31 | $29.88 Billion | $10.35 Billion | 0.347x | +7.71% |
| 2015-12-31 | $28.21 Billion | $9.08 Billion | 0.322x | -3.05% |
| 2014-12-31 | $25.78 Billion | $8.55 Billion | 0.332x | +16.56% |
| 2013-12-31 | $22.10 Billion | $6.29 Billion | 0.285x | -7.74% |
| 2012-12-31 | $19.06 Billion | $5.88 Billion | 0.309x | +14.72% |
| 2011-12-31 | $19.03 Billion | $5.12 Billion | 0.269x | +11.30% |
| 2010-12-31 | $23.94 Billion | $5.79 Billion | 0.242x | -13.54% |
| 2009-12-31 | $22.67 Billion | $6.34 Billion | 0.280x | -4.84% |
| 2008-12-31 | $20.39 Billion | $5.99 Billion | 0.294x | -2.82% |
| 2007-12-31 | $17.87 Billion | $5.40 Billion | 0.302x | +6.36% |
| 2006-12-31 | $18.96 Billion | $5.39 Billion | 0.284x | +18.34% |
| 2005-12-31 | $20.45 Billion | $4.91 Billion | 0.240x | +27.99% |
| 2004-12-31 | $19.70 Billion | $3.70 Billion | 0.188x | +2.33% |
| 2003-12-31 | $19.45 Billion | $3.57 Billion | 0.183x | +49.09% |
| 2002-12-31 | $18.29 Billion | $2.25 Billion | 0.123x | -56.65% |
| 2001-12-31 | $5.22 Billion | $1.48 Billion | 0.284x | -25.11% |
| 2000-12-31 | $4.31 Billion | $1.63 Billion | 0.379x | +6.53% |
| 1999-12-31 | $3.02 Billion | $1.08 Billion | 0.356x | -12.51% |
| 1998-12-31 | $2.56 Billion | $1.04 Billion | 0.406x | -3.69% |
| 1997-12-31 | $2.14 Billion | $902.90 Million | 0.422x | -2.19% |
| 1996-12-31 | $1.91 Billion | $822.60 Million | 0.432x | -6.70% |
| 1995-12-31 | $1.67 Billion | $773.20 Million | 0.462x | +10.80% |
| 1994-12-31 | $1.27 Billion | $531.90 Million | 0.417x | +12.98% |
| 1993-12-31 | $1.17 Billion | $433.00 Million | 0.369x | +17.81% |
| 1992-12-31 | $933.70 Million | $292.80 Million | 0.314x | -24.19% |
| 1991-12-31 | $531.10 Million | $219.70 Million | 0.414x | +1119.56% |
| 1990-12-31 | $398.00 Million | $13.50 Million | 0.034x | -65.88% |
| 1989-12-31 | $188.10 Million | $18.70 Million | 0.099x | +372.80% |
| 1988-12-31 | $161.90 Million | $-5.90 Million | -0.036x | -- |
About Amgen Inc
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women wi… Read more